Compare APLE & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLE | OGN |
|---|---|---|
| Founded | 2007 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2007 | 2020 |
| Metric | APLE | OGN |
|---|---|---|
| Price | $18.10 | $13.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | ★ $17.28 | $11.25 |
| AVG Volume (30 Days) | ★ 2.2M | 2.0M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.29% | 0.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.40 | ★ 0.95 |
| Revenue | $1,238,622,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $2.12 | $2.51 |
| P/E Ratio | $45.59 | ★ $14.48 |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $10.85 | $5.69 |
| 52 Week High | $18.30 | $13.83 |
| Indicator | APLE | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 76.65 | 54.03 |
| Support Level | $15.97 | $13.46 |
| Resistance Level | N/A | $13.77 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 90.43 | 34.78 |
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.